<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233635</url>
  </required_header>
  <id_info>
    <org_study_id>0507061</org_study_id>
    <nct_id>NCT01233635</nct_id>
  </id_info>
  <brief_title>Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)</brief_title>
  <official_title>Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <brief_summary>
    <textblock>
      In the present application, we propose to refine and extend current insight into AAF
      mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE
      genotype, and their interaction in secondary AF prevention. We have 3 specific aims:

        1. To confirm that RAAS inhibition therapy reduces the incidence of AF recurrence.

        2. To test the hypothesis that the incidence of AF recurrence in the absence of RAAS
           inhibition therapy is higher among patients with the D allele.

        3. To explore the hypothesis that RAAS inhibition therapy is more effective for preventing
           AF recurrence in patients with the DD genotype than in those with DI or II genotypes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inadequate enrollment rate
  </why_stopped>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AF burden</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>A Group 1 no drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have not taken ACE/ARB, randomized to no drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have not taken ACE/ARB, randomized to take cozaar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients currently taking ACE/ARB will have their prescription changed to cozaar.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no drug</intervention_name>
    <description>none, no drug</description>
    <arm_group_label>A Group 1 no drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>start cozaar</intervention_name>
    <description>start cozaar</description>
    <arm_group_label>A Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continue cozaar</intervention_name>
    <description>continue cozaar</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be in atrial fibrillation confirmed by 12 lead EKG.

          -  blood pressure &gt; 90 mmHg

          -  Patient without cardiopulmonary symptoms

          -  18+ years of age

        Exclusion Criteria:

          -  Contraindiction to warfarin

          -  Recent (within 6 months) MI or cardiac revascularization

          -  Recent (within 6 months) CVA or TIA

          -  NYHA Class IV CHF

          -  Active thyroid disease

          -  Major hepatic dysfunction

          -  Renal dysfunction (&gt;2 mg/dL)

          -  Hyperkalemia (&gt;4.6 mEq/L)

          -  Hyponatremia (&lt;130 mEq/L)

          -  Currently taking a Vaughn-Williams Type I or III antiarrhythmic drug

          -  History of ARB intolerance

          -  Contraindication to ARB therapy

          -  Pregnancy

          -  Female of childbearing age

          -  Age &lt; 18 years of age

          -  Inability to give informed consent

          -  Other medical conditions calling 1 year survival into question
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UPMC CVI</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

